Orchestra BioMed Overview
- Year Founded
-
2017
- Status
-
Public
- Employees
-
56
- Stock Symbol
-
OBIO
- Investments
-
4
- Share Price
-
$2.83
- (As of Wednesday Closing)
Orchestra BioMed General Information
Description
Orchestra BioMed Holdings Inc is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships. Its partnership-enabled business model focuses on forging strategic collaborations with medical device companies to drive the commercialization of the products it develops. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension and Virtue Sirolimus AngioInfusionBalloon (SAB) for the treatment of atherosclerotic artery disease.
Contact Information
Website
www.orchestrabiomed.comCorporate Office
- 150 Union Square Drive
- New Hope, PA 18938
- United States
Corporate Office
- 150 Union Square Drive
- New Hope, PA 18938
- United States
Orchestra BioMed Stock Performance
As of 23-Apr-2025, Orchestra BioMed’s stock price is $2.83. Its current market cap is $109M with 38.3M shares.
(As of Wednesday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $2.83 | $2.86 | $2.49 - $8.87 | $109M | 38.3M | 291K | -$1.66 |
Orchestra BioMed Financials Summary
As of 31-Dec-2024, Orchestra BioMed has a trailing 12-month revenue of $2.64M.
|
In Thousands, USD |
TTM 31-Dec-2024 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 |
|---|---|---|---|---|
| EV | 86,966 | 86,966 | 228,955 | |
| Revenue | 2,638 | 2,638 | 2,760 | 3,533 |
| EBITDA | (64,072) | (64,072) | (52,682) | (33,436) |
| Net Income | (61,024) | (61,024) | (49,120) | (33,608) |
| Total Assets | 76,173 | 76,173 | 95,212 | 95,572 |
| Total Debt | 16,529 | 16,529 | 1,687 | 11,870 |
Orchestra BioMed Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Orchestra BioMed Comparisons
Industry
Financing
Details
Orchestra BioMed Competitors (53)
One of Orchestra BioMed’s 53 competitors is Humacyte, a Formerly VC-backed company based in Durham, NC.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Humacyte | Formerly VC-backed | Durham, NC | ||||
| Axsome Therapeutics | Corporation | New York, NY | ||||
| Krystal Biotech | Formerly VC-backed | Pittsburgh, PA | ||||
| Capricor Therapeutics | Formerly VC-backed | San Diego, CA | ||||
| ACADIA Pharmaceuticals | Formerly VC-backed | San Diego, CA |
Orchestra BioMed Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Orchestra BioMed Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Orchestra BioMed Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Orchestra BioMed Investments & Acquisitions (4)
Orchestra BioMed’s most recent deal was a Later Stage VC with Vivasure Medical for . The deal was made on 14-Mar-2023.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Vivasure Medical | 14-Mar-2023 | Later Stage VC | Surgical Devices | ||
| Health Sciences Acquisitions Corporation 2 | 27-Jan-2023 | Merger/Acquisition | Special Purpose Acquisition Company (SPAC) | ||
| BackBeat Medical | 01-Jul-2018 | Merger/Acquisition | Therapeutic Devices | ||
| Caliber Therapeutics | 01-May-2018 | Merger/Acquisition | Biotechnology |
Orchestra BioMed ESG
Risk Overview
Risk Rating
Updated March, 14, 2025
34.94 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 15,109
Rank
Percentile
Healthcare
Industry
of 587
Rank
Percentile
Medical Devices
Subindustry
of 198
Rank
Percentile
Orchestra BioMed FAQs
-
When was Orchestra BioMed founded?
Orchestra BioMed was founded in 2017.
-
Where is Orchestra BioMed headquartered?
Orchestra BioMed is headquartered in New Hope, PA.
-
What is the size of Orchestra BioMed?
Orchestra BioMed has 56 total employees.
-
What industry is Orchestra BioMed in?
Orchestra BioMed’s primary industry is Therapeutic Devices.
-
Is Orchestra BioMed a private or public company?
Orchestra BioMed is a Public company.
-
What is Orchestra BioMed’s stock symbol?
The ticker symbol for Orchestra BioMed is OBIO.
-
What is the current stock price of Orchestra BioMed?
As of 23-Apr-2025 the stock price of Orchestra BioMed is $2.83.
-
What is the current market cap of Orchestra BioMed?
The current market capitalization of Orchestra BioMed is $109M.
-
What is Orchestra BioMed’s current revenue?
The trailing twelve month revenue for Orchestra BioMed is $2.64M.
-
Who are Orchestra BioMed’s competitors?
Humacyte, Axsome Therapeutics, Krystal Biotech, Capricor Therapeutics, and ACADIA Pharmaceuticals are some of the 53 competitors of Orchestra BioMed.
-
What is Orchestra BioMed’s annual earnings per share (EPS)?
Orchestra BioMed’s EPS for 12 months was -$1.66.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
